Cancer and immunotherapy: a role for microbiota composition.

Area of Science:

• Microbiome research
• Cancer immunology
• Pharmacology

Background:

• The human gut microbiota is crucial for maintaining health and homeostasis.
• Alterations in gut microbiota composition are linked to various diseases.
• Recent research highlights the gut microbiome's potential role in cancer treatment response.

Purpose of the Study:

• To review the relationship between microbiome composition and response to immune checkpoint blockers (ICBs).
• To explore the influence of microbiota-derived metabolites on ICB efficacy and immune-related adverse events.
• To discuss strategies for modulating the gut microbiota to improve cancer treatment outcomes.

Main Methods:

• Literature review of studies investigating the gut microbiome and ICB therapy.
• Analysis of data correlating microbiome composition with patient response to ICBs.
• Examination of research on microbiota-derived metabolites and their impact on cancer treatment.

Main Results:

• Gut microbiota composition is associated with patient response to ICBs.
• Specific microbial metabolites may predict or influence ICB efficacy.
• Microbiota modulation strategies are being explored to enhance treatment outcomes.

Conclusions:

• The gut microbiome represents a promising biomarker for predicting ICB response in cancer patients.
• Targeting the microbiome offers potential for improving ICB efficacy and managing toxicities.
• Microbiome modulation could emerge as a complementary approach in cancer therapy.